A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients

Trial Profile

A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 May 2017

At a glance

  • Drugs Valsartan/hydrochlorothiazide (Primary) ; Amlodipine; Hydrochlorothiazide
  • Indications Hypertension; Obesity
  • Focus Therapeutic Use
  • Acronyms VITAE
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2010 Results, detailing the comparative effects of valsartan/hydrochlorothiazide with those of hydrochlorothiazide + amlodipine on fasting and post-prandial glucose and insulin levels, have been published in the Journal of Hypertension.
    • 28 Oct 2008 Actual patient number (412) added as reported by ClinicalTrials.gov.
    • 28 Oct 2008 Actual end date (Nov 2007) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top